ACHV

Business Context and Reporting Period

Company: OncoGenex Pharmaceuticals, Inc. (Note: Metadata listed "ACHIEVE LIFE SCIENCES, INC." but the filing text confirms the registrant is OncoGenex Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: A biopharmaceutical company developing cancer therapies to address treatment resistance. The primary focus is the development of custirsen (OGX-011) in collaboration with Teva Pharmaceutical Industries Ltd., alongside other candidates including OGX-427, OGX-225, SN2310, and CSP-9222.

Key Financial Metrics

Liquidity: As of September 30, 2010, the company held approximately $42.1 million in cash, cash equivalents, and short-term investments. The company has no borrowing or credit facilities available.

Material Changes vs. Prior Period

• Revenue: Collaboration revenue increased from $0 in the prior year periods to $11.3 million for the nine months ended September 30, 2010. This is due to the recognition of deferred revenue from the Teva Collaboration Agreement signed in December 2009.
• Expenses: Total expenses rose significantly to $24.1 million (nine months 2010) from $9.5 million (nine months 2009).
  • R&D Expenses: Increased to $16.2 million (from $6.3 million) driven by manufacturing and clinical trial costs for custirsen Phase 3 trials.
  • Restructuring Expense: A non-cash charge of $4.0 million was recorded in Q3 2010 due to revised sublease income assumptions regarding excess office space in Bothell, WA. This compares to $0.5 million in the prior year period.
• Income Tax: A $3.0 million income tax recovery was recorded in Q2 2010 after the Israeli Tax Authority approved a withholding tax exemption on Teva payments.
• Cash Position: Cash and cash equivalents decreased from $62.1 million at year-end 2009 to $11.8 million at September 30, 2010, primarily due to operating cash outflows and investment purchases.

Guidance, Outlook, and Risks

Outlook and Capital Resources:

• Management expects current capital resources, combined with net proceeds of approximately $46.7 million from a public offering completed on October 22, 2010, and $0.5 million in research grants awarded in November 2010, to fund operations into late 2014.
• Anticipated operating expenses for 2010 are between $30 million and $32 million.
• Expected year-end 2010 cash position (including receivables) is between $82 million and $84 million.

Key Risks and Contingencies:

• Clinical Trial Uncertainty: Success depends on the results of Phase 3 trials for custirsen (SATURN and SYNERGY trials) and future trials for other candidates.
• Dependence on Teva: The company relies on Teva's commitment and funding for the commercialization of custirsen.
• Lease Liability: A significant liability of $7.8 million remains regarding excess office space in Bothell, WA, with potential future costs if subleasing is unsuccessful.
• Intellectual Property: Obligations to pay royalties and milestones to Isis Pharmaceuticals and the University of British Columbia (UBC) based on future sales and milestones.

Investor Verification Checklist

• Subsequent Financing: Verify the closing and net proceeds of the $50 million public offering completed on October 22, 2010.
• Restructuring Liability: Monitor the status of the $7.8 million excess lease facility liability and the company's ability to sublet the Bothell, WA facility.
• Clinical Trial Progress: Track enrollment and preliminary data for the SATURN and SYNERGY Phase 3 trials for custirsen.
• Deferred Revenue Recognition: Review the amortization schedule for the remaining $23 million of deferred collaboration revenue from Teva.
• Grant Funding: Confirm receipt of the $489,000 in therapeutic discovery research grants awarded in November 2010.